Neutrophil activation by immune response modifier compounds

Details Neutrophil activation by immune response modifier compounds Neutrophil activation by immune response modifier compounds

A - Human Necessities

61

K

A61K 31/4745 (2006.01) A61K 31/4738 (2006.01) A61K 45/06 (2006.01)

Patent

CA 2543685

The invention provides a method of activating neutrophils. Generally, the method includes contacting neutrophils with a neutrophil-activating IRM compound and/or aTLR8-selective agonist in an amount effective to activate the neutrophils. In some embodiments, the method may be used to treat a condition treatable by activating neutrophils. In another aspect, the invention provides pharmaceutical compositions that generally include a neutrophil-activating IRM compound and/or a TLR8-selective agonist, or a pharmaceutically acceptable form thereof, in an amount effective to activate neutrophils.

L'invention concerne un procédé d'activation des neutrophiles. D'une façon générale, le procédé consiste à mettre les neutrophiles en contact avec un composé modificateur de la réponse immunitaire (IRM) activant les neutrophiles et/ou un agoniste sélectif des TLR8 en quantité suffisante pour activer les neutrophiles. Dans certains modes de réalisation, le procédé peut servir à traiter une condition se traitant par activation des neutrophiles. Dans un autre aspect, l'invention concerne des compositions pharmaceutiques qui incluent généralement un composé IRM activant les neutrophiles et/ou un agoniste sélectif des TLR8, ou l'une de ses formes pharmaceutiquement admises, en quantité suffisante pour activer les neutrophiles.

Affiliated with

Also associated with

Rating

Neutrophil activation by immune response modifier compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Neutrophil activation by immune response modifier compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Neutrophil activation by immune response modifier compounds will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1649490